Please login to the form below

Not currently logged in
Email:
Password:

Deal Watch table for November 2014

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during November 2014.

For an indepth analysis of these deals, read 'Pharma deals during November 2014'

Licensor acquired / licensee acquirer

Product / technology

Deal type

Headline ($m)

Allergan / Actavis
Dermatology / ophthalmology portfolio
Company acquisition
66,000
Omega Pharma / Perrigo
OTC portfolio
Company acquisition
4,500
Cystic Fibrosis Foundation /Royalty Pharma
Vertex's CF portfolio
Royalty stream acquisition
3,300
Indivior  / Reckitt Benckiser
Pharma business unit
Business unit divestment
3,200
Almirall / AstraZeneca
Eklira and Duaklir
Business unit acquisition
3,075
Pfizer / Merck KGaA
PD-L1 and PD-1 CP inhibitors
Co-development and co-marketing alliance
2,850
UCB (Kremers Urban Pharma) /Advent International and Avista Capital Partners
Generics portfolio
Company divestment
1,530
Proteostasis Therapeutics / Astellas
Therapeutics modulating Unfolded Protein Response - multiple programmes
Discovery collaboration
1,200
Intacia / Servier
ICTA 650 (injection free GLP-1 agonist)
Licence
1,051
Geron Corporation / J&J (Janssen)
GRN163L, Imetelstat and tolerase inhibitor
Licence
935
Prosensa / BioMarin
Drisapersen – for Duchenne muscular dystrophy
Company acquisition
840
Galecto Biotech / BMS
TD139 galectin-3 inhibitor for Idiopathic pulmonary fibrosis
Option
444
AstraZeneca / Aegerion
Myalet (metreleptin) injection for leptin deficiency
Product acquisition
325
Transposagen Biopharmaceuticals/ J&J (Janssen)
Allogeneic Chimeric Antigen Receptor T-cells (CAR-T) therapies
Licence & research collaboration
292
Modern Biosciences / J&J (Janssen Biotech)
Bone protection compounds in RA
Research collaboration
275
Definiens / AstraZeneca (through MedImmune)
Tissue Phenomics Dx oncology biomarkers
Company acquisition
150
Knight Therapeutics / Gilead Sciences
Priority review voucher for Miltefosine
Acquisition of voucher
125
AVEO Oncology / Ophthotech Corporation
VEGF tyrosine kinase inhibitor tivozanib
Research and exclusive option to license
106
University of Michigan / PDL Biopharma
Cerdelga (eliglustat) sold by Vertex
Acquisition 75% royalty stream
66
Five Prime Therapeutics / BMSFPA008 mAb inhibits (CSF1R) to be combined with nivolumab (PD-1 check-point inhibitor)Research collaboration30


The Deal Watch table is compiled by Medius Associates

9th December 2014

The Deal Watch table is compiled by Medius Associates

9th December 2014

From: Research, Sales

Share

Tags


Career advice

No results were found

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Infographics